This is a guest post from Michael D. Hooven, President & CEO, Enable Injections Inc. The oxpecker perches on the backs […]
Solving the problem of biologic delivery: Large volume wearable injectors Read Post »
Hermann A. M. Mucke*, H. M. Pharma Consultancy, Wien, Austria A Multimodal Approach to the Re-development of Drugs Drug repositioning—the investigation, development and use of active pharmaceutical ingredients for a…
The post Drug Repositioning in the …
Drug Repositioning in the Mirror of Patenting: Surveying and Mining Uncharted Territory Read Post »
This is a guest post from Craig Stropkay. Craig is Director and Life Science Consultant at KOLgroups, LLC Reach for the
These are relative terms. If I license a product from you, I am in-licensing it and you are out-licensing it.
What is in licensing and out licensing in pharmaceutical sector? Read Post »
This is a guest post from Steve Kirsh. Steve is Founder + Managing Partner of Khameleon Group. When was the
3 Tips for Finding the Right Talent for Your Biotech Startup Read Post »
This is a guest post from Avneet Heer, a student in the MS Biotechnology BioBusiness Track at Georgetown University. Do
How do biotech venture investments in public equities (known as VIPEs) perform? Do they outperform mutual funds and hedge funds?
Biotech venture capital investments in public equities and performance Read Post »
How do biotech stocks behave during the first day of trading? How do they perform in the long-run period? What
Leaving money on the table in venture-backed biotechnology IPOs Read Post »
After months of development and feedback from customers, DrugPatentWatch is proud to announce the availability of two new datasets: Bulk
New features from DrugPatentWatch – Bulk API sources and clinical trials Read Post »
This is a guest post from Mark D. Shtilerman1 and Joseph Eng Jr. Dr. Shtilerman is Senior Counsel at Deerfield
Get new actionable insights and updates from BiotechBlog
